Search hospitals > Ontario > BARRIE
Barrie GI Associates
Claim this profileBARRIE, Ontario L4M 7G1
Conducts research for Crohn's Disease
Conducts research for Psychogenic Colitis
Conducts research for Ulcer
Conducts research for Ulcerative Colitis
Conducts research for Colitis
10 reported clinical trials
0 medical researchers
Summary
Barrie GI Associates is a medical facility located in BARRIE, Ontario. This center is recognized for care of Crohn's Disease, Psychogenic Colitis, Ulcer, Ulcerative Colitis, Colitis and other specialties. Barrie GI Associates is involved with conducting 10 clinical trials across 6 conditions. There are 0 research doctors associated with this hospital, such as .Top PIs
Clinical Trials running at Barrie GI Associates
Crohn's Disease
Ulcerative Colitis
Psychogenic Colitis
Ulcer
Colitis
Crohn's disease
Tulisokibart
for Crohn's Disease
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).
Recruiting1 award Phase 31 criteria
RO7790121
for Crohn's Disease
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Recruiting1 award Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Barrie GI Associates?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.